Changes in the structure or number of chromosomes in certain cells of the bone marrow.
« Back to Glossary IndexNews
Related News
My lab’s vision for the next five years is to apply what we have learned to develop molecules that can alter FA protein behavior. These could be used to treat cancer or alter gene editing outcomes.
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.
We’re thrilled to share that Rena and Paul Rice, parents of two children with Fanconi anemia—Sydney (19) and Blake (25)—have made an extraordinary commitment to the FA community: a gift of $100,000 per year for the next three years to...